Project Grant R01AR084705
- This Project Grant award for $300,000 from the Department of Health and Human Services' National Institutes of Health (CFDA 93.310 Trans-NIH Research Support) to Brigham & Women's Hospital Inc. (a subsidiary of Partners Healthcare System) supports research on the role of activated neutrophils and T cells in the pathogenesis of systemic lupus erythematosus (SLE), lupus nephritis, and vasculitis. The research aims to investigate how immune cell abnormalities, specifically the generation of...
- This $256,808 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to better define the molecular mechanisms that cause and perpetuate systemic lupus erythematosus (SLE). The University of Washington is conducting this research, which focuses on analyzing altered mRNA splicing in SLE neutrophils and exploring the consequences of these splicing changes, including...
- This federal Project Grant award, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research into the functions of the LYNA and LYNB kinases in myeloid-cell pro-inflammatory signaling and their relationship to systemic lupus erythematosus (SLE). The $668,135 award, effective from Sep 1, 2025 to Aug 31, 2030, aims to assess the roles of these kinase...
- This federal Project Grant award for $3,364,935.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) through the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to functionally and mechanistically characterize genetic factors that contribute to the development of systemic lupus erythematosus (SLE). The research aims to elucidate the role of autophagy, a cellular process, in the pathogenesis of SLE, particularly in immune cells and...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $715,957.00 to Northwestern University to conduct research on the mechanisms by which type I interferon cytokines support the production and expansion of T peripheral helper (Tph) cells in systemic lupus erythematosus (SLE) patients. The research aims to elucidate the molecular pathways...
- The federal Project Grant award of $300,000 was provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) to Temple University in Philadelphia, PA. The funding supports research focused on understanding the role of the kallikrein-kinin system and its ability to suppress the type I interferon response, which is a hallmark of systemic lupus erythematosus (SLE). The research aims to explore new pathways for interferon suppression and their...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research to characterize hematopoietic stem cell (HSC) impairment in a mouse model of systemic lupus erythematosus (SLE)-like disease. The $216,113 award to New York University School of Medicine will be used to test the hypothesis that SLE-like disease impairs HSC activity, potentially...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) in the amount of $235,500 supports the development of a novel Trispecific Killer Cell Engager (TRIKE) for the treatment of Systemic Lupus Erythematosus (SLE). The objective is to engineer a TRIKE that can effectively engage and activate natural killer (NK) cells with high affinity, thereby facilitating the efficient clearance of pathogenic immune...
- This $375,100 federal Project Grant award was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant funds a study to investigate the interplay between nucleic-acid-dependent phase separation and immune responses against cyclic GMP-AMP synthase (cGAS) in systemic lupus erythematosus (SLE). The research aims to determine how changes in the biophysical...
- The University of Massachusetts Medical School was awarded a $494,929 Project Grant from the National Institute of Allergy and Infectious Diseases to study the role of Toll-like receptors, type II interferon and type III interferon in a murine model of autoinflammation. The grant will support research exploring the effector mechanisms responsible for inducing and regulating cutaneous lupus using genetically modified mice with discriminating mutations. Specifically, the researchers will use...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $637,018 to Rutgers, The State University of New Jersey to investigate the role of natural killer (NK) cells in regulating humoral immune responses during systemic lupus erythematosus (lupus). The 5-year project aims to dissect the effects of NK cell, T follicular helper (Tfh) cell, and B cell interactions on autoantibody production and lupus disease progression. Key research activities include investigating NK cell regulation of Tfh cells, germinal center B cells, and age-associated B cells, as well as assessing the cellular and molecular mechanisms underlying NK cell-mediated regulation of humoral immunity in lupus. The project also plans to test novel therapeutic agents designed to promote NK cell-mediated killing of Tfh cells and B cells as potential lupus treatments. This award supports critical research to advance the understanding of NK cell functions in autoimmune conditions and explore new therapeutic approaches.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $637.0k | 8/6/25 |